Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 8/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 6/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304464 | 0.84 | TXNRD1 (0.42) | TXNRD1LRRK2SOS1 | |
| SCHEMBL28043082 | 0.78 | TXNRD1 (0.39) | TXNRD1 | |
| SCHEMBL28042893 | 0.78 | TXNRD1 (0.39) | TXNRD1 | |
| SCHEMBL1032611 | 0.78 | CHRNB2 (0.40) | TXNRD1 | |
| SCHEMBL2835065 | 0.78 | LRRK2 (0.40) | LRRK2GRM5DRD3PDE2APDE10A | |
| SCHEMBL16178461 | 0.78 | LRRK2 (0.40) | LRRK2SOS1GRM5DRD3PDE2A | |
| SCHEMBL28390133 | 0.76 | LRRK2 (0.37) | LRRK2GRM5DRD3PDE2APDE10A | |
| SCHEMBL15674241 | 0.74 | MERTK (0.47) | TXNRD1LRRK2 | |
| SCHEMBL1428159 | 0.72 | TXNRD1 (0.58) | TXNRD1 | |
| SCHEMBL15086913 | 0.72 | LRRK2 (0.41) | LRRK2SOS1GRM5PDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776445-B1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-08-10 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2776445-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068458-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | TXNRD1 350/4885LRRK2 2615/4885SOS1 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.